The latest NFL Power Rankings have the Rams surging as they prepare for a pivotal matchup against the Seahawks. With playoff hopes on the line, find out where each team stands at midseason!
A groundbreaking study reveals that scientists have discovered a method to reprogram the pancreas to produce GLP-1s naturally, eliminating the need for Ozempic and offering new hope for sustainable weight loss.
This Saturday's UFC 322 features Islam Makhachev and Zhang Weili vying for double champion status. Will they succeed against formidable opponents Jack Della Maddalena and Valentina Shevchenko? Anticipation is high as experts weigh in!
Despite losing a $10 billion bid for Metsera to Pfizer, Novo Nordisk's CEO Mike Doustdar remains determined to pursue new opportunities in the obesity and diabetes sectors. The company aims to reclaim its position in the booming weight-loss market.
UFC Vegas 111 kicks off with controversy as Ismael Bonfim misses weight by five pounds, jeopardizing his fight against Chris Padilla. Meanwhile, Gabriel Bonfim is set for his main event clash.
Eli Lilly & Co. and Novo Nordisk A/S have struck a deal with the Trump administration to lower prices for their popular weight-loss drugs, Zepbound and Wegovy, while gaining tariff relief and expanding Medicare access. This agreement aims to increase availability for older Americans.
In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
In a groundbreaking move, President Trump has negotiated significant price reductions for popular weight loss medications, bringing costs down to as low as $50 per month for eligible patients. Find out how these changes will affect access to essential treatments!
In a groundbreaking move, President Trump announces deals with Eli Lilly and Novo Nordisk to reduce obesity drug prices, making treatments more accessible for millions of Americans. Medicare coverage for GLP-1 drugs starts in 2026, changing the landscape of obesity treatment.
Two biotech companies are developing groundbreaking gene therapies that could lead to a single injection for weight loss and blood sugar control. Initial tests show promising results in mice, with human trials on the horizon.